Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer that arises
from the skeletal muscle. Recent studies have identified an important role of AKT signaling …

Despite the advances of adjuvant chemotherapy and significant improvement of survival, the
prognosis for patients with osteosarcoma is generally poor. The search for more effective …

Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma including
two major subtypes, alveolar rhabdomyosarcoma (ARMS) and embryonal …

Perifosine is a synthetic novel alkylphospholipid, a new class of antitumor agents which
targets cell membranes and inhibits Akt activation. Here we show that baseline …

Our long-term research goal is to develop efficacious regimens for cancer therapy through
our understanding of cancer biology and drug mechanisms. Perifosine is an …

Chemoresistance is a major problem in the treatment of Neuroblastoma (NB). Our studies
first showed that constitutive or growth factor induced activation of Akt induced …

Perifosine treatment exhibits a complex molecular response including the inhibition of Akt or
the induction of apoptosis via clustering of death receptors in lipid rafts. However, the …

Alveolar rhabdomyosarcoma (ARMS) is the aggressive subtype of muscle cancer in the
pediatric population and children with ARMS have significantly poor prognosis and …

Background Activated AKT is a marker of decreased event-free or overall survival in
neuroblastoma (NB) patients. The aim of this study was to investigate the effect of perifosine …

Perifosine (NSC 639966; Keryx Biopharmaceuticals, New York, NY) is a synthetic novel
alkyl-lysophospholipid, a new class of anti-tumor agents which targets cell membranes and …